SLC7A11 and ovarian carcinoma: Finally, external validation in larger, independent patient cohorts and prospective clinical studies will be essential to confirm the prognostic and predictive value of GPAT4/SLC7A11 co-expression, particularly in the context of platinum resistance in epithelial ovarian cancer (EOC).